-
2m 57sPart 1 | Session 3 AdmIRE: Predicting Recurrent Atrial Arrhythmias
-
12m 52sPart 1 | Session 4 MANIFEST-REDO: Re-Do Procedures After PFA for AF
-
7m 16s
-
6m 24sPart 2 | Session 1 4 Trials That Will Change My Practice With Dr Luigi Di Biase
-
3m 5sPart 2 | Session 2 Highlights with Dr Ronghua Yang
AF Symposium 25 - Safety and effectiveness results show the Volt (Abbott) pulsed field ablation (PFA) system for pulmonary vein isolation (PVI) is a successful treatment option for paroxysmal and persistent atrial fibrillation patients.
Prof Roland Tilz (University Heart Centre Lübeck, Lübeck, DE) joins us onsite at AF Symposium 25 to discuss the findings of balloon-based PFA for PVI. The pre-market, single-arm study's safety endpoint was major adverse events within 7 days post-ablation, and the efficacy endpoint was arrhythmia recurrence within 6 months post-ablation.
Findings revealed that the Volt PFA system met its safety and efficacy endpoints with a low occurrence of major adverse events.
Interview Questions:
1. What is the reasoning behind the trial?
2. What was the study design, safety endpoints and patient population?
3. What are the key findings?
4. What are the take-home messages for practice?
5. What further study is needed?
Recorded on-site at AF Symposium in Boston, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles, David Ben-Harosh
Interviewer: David Ramsey
Support: This is an independent interview produced by Arrhythmia Academy.
Stay up to date with our video collection covering late-breaking data from AF Symposium 2025 in Boston. Don't miss our short, accessible Expert Interviews and Highlights of the most pertinent trials.
More from this programme
Faculty Biographies
Roland R Tilz
Prof Roland Tilz is the deputy director of the Medical Center II of the University Hospital in Lübeck and professor of the invasive electrophysiology at the University Lübeck. He is committed to training in the field of “Invasive electrophysiology and cardiac rhythm implants”. Prof Roland Tilz trained at the Addenbrooks Hospital in Cambridge (UK), Bedford Hospital (UK), Klinikum Bayreuth and at the Asklepios Klinik St. Georg in Hamburg.
Comments